Cargando…

Palbociclib has no clinically relevant effect on the QTc interval in patients with advanced breast cancer

The aim of this study was to assess the potential effects of palbociclib in combination with letrozole on QTc. PALOMA-2, a phase 3, randomized, double-blind, placebo-controlled trial, compared palbociclib plus letrozole with placebo plus letrozole in postmenopausal women with estrogen receptor-posit...

Descripción completa

Detalles Bibliográficos
Autores principales:	Durairaj, Chandrasekar, Ruiz-Garcia, Ana, Gauthier, Eric R., Huang, Xin, Lu, Dongrui R., Hoffman, Justin T., Finn, Richard S., Joy, Anil A., Ettl, Johannes, Rugo, Hope S., Zheng, Jenny, Wilner, Keith D., Wang, Diane D.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2018
Materias:	Clinical Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5821476/ https://www.ncbi.nlm.nih.gov/pubmed/29360661 http://dx.doi.org/10.1097/CAD.0000000000000589

Ejemplares similares

Palbociclib with Letrozole in Postmenopausal Women with ER+/HER2− Advanced Breast Cancer: Hematologic Safety Analysis of the Randomized PALOMA‐2 Trial
por: Diéras, Véronique, et al.
Publicado: (2019)

Impact of Dose Reduction on Efficacy: Implications of Exposure-Response Analysis of Palbociclib
por: Zheng, Jenny, et al.
Publicado: (2020)

Talazoparib has no clinically relevant effect on QTc interval in patients with advanced solid tumors
por: Hoffman, Justin, et al.
Publicado: (2019)

Hematologic adverse events following palbociclib dose reduction in patients with hormone receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer: pooled analysis from randomized phase 2 and 3 studies
por: Ettl, Johannes, et al.
Publicado: (2020)

Treatment effect of palbociclib plus endocrine therapy by prognostic and intrinsic subtype and biomarker analysis in patients with bone-only disease: a joint analysis of PALOMA-2 and PALOMA-3 clinical trials
por: Finn, Richard S., et al.
Publicado: (2020)

Long-term Pooled Safety Analysis of Palbociclib in Combination With Endocrine Therapy for HR+/HER2- Advanced Breast Cancer
por: Diéras, Véronique, et al.
Publicado: (2018)

Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up
por: Rugo, H. S., et al.
Publicado: (2019)

Efficacy and safety of palbociclib plus endocrine therapy in North American women with hormone receptor‐positive/human epidermal growth factor receptor 2‐negative metastatic breast cancer
por: Gelmon, Karen A., et al.
Publicado: (2019)

Comparative biomarker analysis of PALOMA-2/3 trials for palbociclib
por: Zhu, Zhou, et al.
Publicado: (2022)

A Practical Method for QTc Interval Measurement
por: De Oliveira Neto, Nestor R, et al.
Publicado: (2020)

Long‐Term Pooled Safety Analysis of Palbociclib in Combination with Endocrine Therapy for Hormone Receptor‐Positive/Human Epidermal Growth Factor Receptor 2‐Negative Advanced Breast Cancer: Updated Analysis with up to 5 Years of Follow‐Up
por: Finn, Richard S., et al.
Publicado: (2021)

Problems with Bazett QTc correction in paediatric screening of prolonged QTc interval
por: Andršová, Irena, et al.
Publicado: (2020)

Impact of palbociclib plus letrozole on patient-reported health-related quality of life: results from the PALOMA-2 trial
por: Rugo, H S, et al.
Publicado: (2018)

Incidence and relevance of QTc-interval prolongation caused by tyrosine kinase inhibitors
por: Kloth, J S L, et al.
Publicado: (2015)

Ketamine-induced QTc interval prolongation
por: Singh, Tejinder S. Swaran, et al.
Publicado: (2017)

Ticagrelor-Induced Prolongation of the QTc Interval
por: Ray, Avik, et al.
Publicado: (2019)

The corrected QT (QTc) prolongation in hyperthyroidism and the association of thyroid hormone with the QTc interval
por: Lee, Ye Seung, et al.
Publicado: (2015)

Pridopidine Does Not Significantly Prolong the QTc Interval at the Clinically Relevant Therapeutic Dose
por: Darpo, Borje, et al.
Publicado: (2023)

Effect of Hemodialysis on Corrected QT Interval and QTc Dispersion
por: Sohal, P. M., et al.
Publicado: (2018)

A thorough QTc study demonstrates that olmesartan medoxomil does not prolong the QTc interval
por: Mendell, Jeanne, et al.
Publicado: (2015)

Effect of domperidone on the QTc interval in premature infants
por: Günlemez, A, et al.
Publicado: (2010)

QTc interval prolongation, COVID-19 and chloroquine
por: Wiwanitkit, V.
Publicado: (2020)

QTc interval-dependent body posture in pediatrics
por: Reynisson, Björn, et al.
Publicado: (2020)

Effect of citric-acid dialysate on the QTC-interval
por: ter Meulen, Karlien J., et al.
Publicado: (2021)

Takotsubo Cardiomyopathy and QTc Prolongation with Subsequent Improvement of QTc Interval and Resolution of Apical Ballooning: A Case Report
por: Alvarez Retamales, Violeta, et al.
Publicado: (2020)

Metabolomic patterns associated to QTc interval in shiftworkers: an explorative analysis
por: Campagna, Marcello, et al.
Publicado: (2016)

Patients With Primary Hyperparathyroidism Have Shorter QT/QTc Intervals
por: Stewart, Latoya A, et al.
Publicado: (2021)

Effects of Peginesatide Injection on QTc Interval in Healthy Adults
por: Czerniak, Richard, et al.
Publicado: (2014)

Changes in QTc interval in long-term hemodialysis patients
por: Matsumoto, Yoshihiro, et al.
Publicado: (2019)

Individually Rate Corrected QTc Intervals in Children and Adolescents
por: Andršová, Irena, et al.
Publicado: (2019)

Azithromycin/hydroxychloroquine: QTc interval prolongation: case report
Publicado: (2020)

Relationship of QTc Interval Prolongation with Acute Ischemic Stroke
por: Amin, Osama Shukir Muhammed, et al.
Publicado: (2020)

Methadone abuse: QTc interval prolongation: case report
Publicado: (2020)

Azithromycin/hydroxychloroquine: QTc interval prolongation: case report
Publicado: (2021)

QTc interval prolongation in the patients with primary biliary cholangitis
por: Wang, Zihao, et al.
Publicado: (2021)

Chloroquine for treatment of COVID-19 results in subtherapeutic exposure and prolonged QTc intervals
por: Brüggemann, R.J., et al.
Publicado: (2021)

Real-world comparative effectiveness of palbociclib plus letrozole versus letrozole in older patients with metastatic breast cancer
por: Rugo, Hope S., et al.
Publicado: (2023)

Real-World Effectiveness of Palbociclib Plus Aromatase Inhibitors in African American Patients With Metastatic Breast Cancer
por: Rugo, Hope S, et al.
Publicado: (2023)

Palbociclib Combined with an Aromatase Inhibitor in Patients with Breast Cancer with Lung or Liver Metastases in US Clinical Practice
por: Brufsky, Adam, et al.
Publicado: (2023)

QTc interval prolongation, inflammation, and mortality in patients with COVID-19
por: Gulletta, Simone, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_4debad2qg3ido10viksce3qr2b